Related Experiment Video
Updated: Jul 19, 2026
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Targeting sphingosine-1-phosphate for cancer therapy
1Department of Biology, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182-4614, USA. rsabba@sunstroke.sdsu.edu
Abstract:
This review summarises some important new findings that implicate sphingosine-1-phosphate (S1P) as a potent tumorigenic and angiogenic agent released from cancerous tumours into the tumour microenvironment. Also explored is the novel concept that bioactive lipid signalling molecules, like S1P, can themselves be targets for rational drug design, thereby opening up an entire class of lipidomic-based therapeutics for oncology and other human diseases.
Insights
Sphingosine-1-phosphate (S1P) promotes tumor growth and blood vessel formation. Targeting S1P and other lipid molecules offers a new therapeutic strategy for cancer and other diseases.
Area of Science:
- Oncology
- Lipidomics
- Molecular Biology
Background:
- Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator.
- Tumor microenvironments are complex and influenced by secreted factors.
- Cancer progression involves angiogenesis and tumor growth.
Purpose of the Study:
- To review new findings on S1P's role in tumorigenesis and angiogenesis.
- To explore S1P as a potential drug target in oncology.
- To introduce lipidomic-based therapeutics for cancer treatment.
Main Methods:
- Literature review of recent studies on S1P.
- Analysis of S1P's function in the tumor microenvironment.
- Discussion of drug design strategies targeting lipid signaling.
Main Results:
- S1P is implicated as a key factor in promoting tumor growth.
- S1P acts as a potent angiogenic agent in the tumor microenvironment.
- Bioactive lipids like S1P represent novel targets for drug development.
Conclusions:
- S1P plays a significant role in cancer progression.
- Targeting S1P offers a promising therapeutic avenue in oncology.
- Lipidomic-based therapies hold potential for treating various human diseases.
